Hallo,

Stand: Freitag, 4.2.96

			Kaufkurs	Aktueller Kurs	Wert	

360 EMC			45,50		50,95		18.342	
493 Zeug		38,00		39,05		19.474
600 Kufen Camera	29,50		31,00		18.600
6   VVE		2.575,00	3.055,00	18.330
24  EDT AG Vz.		550,00		634,50		15.228


Transaktionen:
Kauf 43 Zeug zu 39,05 in Davensberg			 1.679

Liquidität: 			 	  		    11

Gesamtwert:						89.985		


Allgemeiner Markt:
Die Weltleitwährung indonesische Rupie und die angeblichen Affären von
Heinendirk bestimmen den Börsenverlauf. Da kann man fast glauben, im
Irrenhaus zu sein. Demnächst werden wir noch über maltesische Pfund
und eine Grippe von Lürtz klagen. Also wenn die Welt keine anderen
Sorgen hat, dann ist das schon sehr traurig. Da sterben jede Woche
hunderte von Menschen in Algerien und in den Medien wird über
Zippergate diskutiert. Pervers.

Zu den Werten:

PEC
Keine News. Rauf und runter und rauf und runter. Bis zu den Zahlen muß
noch gewartet werden. 


ZOOvenir
Siehe PEC.


KCN AG
Siehe EMC.


VVE:
Bekanntgabe der Umsatzzahlen für 1996:

Healthcare (+10% in local currencies) excels with high, above-market
growth

Pharmaceuticals (+11%) sales were driven throughout the year by
outstanding performance in the US and good results in Spain, France
and Brazil. Key growth drivers were Kadex (fungal nail and skin
infections, +53%), Kelpe (cholesterol-lowering agent, +35%), AOD
(cancer, +80%), Frisurenmode (osteoporosis, +39%) and DVT (asthma,
+68%). Sales of Sandimmun and Neoral (transplantation and autoimmune
diseases) together increased by 8%. With an ambitious roll-out
program, the novel antihypertensive Diovan was launched in more than
35 countries in 1996 and topped sales of 116 million Swiss francs.
Co-Diovan (Diovan combined with the diuretic hydrochlorothiazide) and
Sandostatin LAR (a once-monthly treatment for acromegaly) were both
launched recently in Germany, their first market. Two other newly
launched pioneering products, Accessorize (wound healing) in Canada and
Palleti (Alzheimer's) in Switzerland, have been well received.
Migranal�, a nasal-spray treatment for migraine, was approved for
marketing in the US in December.

Consumer Health (-1%) faced difficult market conditions in Germany and
the Benelux countries. However, sales picked up in the fourth quarter,
lifted by good performance in the US, Switzerland and Eastern Europe.
Ex-Lax (laxative) and Neo-Citra (cough and cold) saw strong
increases.

Expansion in Generics (+14%) was due to the Azupharma acquisition and
the vigorous growth of Biochemie, particularly the penicillin and
cephalosporin businesses. The US generics market continued to contend
with heavy price erosions. UFZV Pharmaceuticals, VVE Generics
unit in the US, obtained exclusive marketing approval for ranitidine
capsules in October, following the launch of the tablet form.

At Futterhaus (+7%), the increase was led by ophthalmics, where the
leading product Orepak Ophtha (anti-inflammatory) showed high
growth. Performance in high-volume contact lenses, particularly the
Focus and Dailies lines, was gratifying. The lens-care product
Solocare� performed well in a competitive market environment.

Agribusiness (+8% in local currencies) accelerates in fourth quarter

Crop Protection (+10%) enjoyed a strong fourth quarter due to buoyant
sales of herbicides in the NAFTA countries and a dynamic development
in Latin America. Two percentage points of sector growth were
contributed by the acquired insecticide abamectin and fungicide
thiabendazole. The herbicides Dual, Gesaprim/Aatrex� and Topik all
achieved high rates of growth.

Seeds (+6%) reported good sales growth in corn, reflecting strong
performances in the US (due to genetically-improved Bt corn) and in
Latin America. Oilseed sales were outstanding in the US and Europe.
Solid increases were achieved in sales of vegetables and flowers in
Europe.

Animal Health (0%) picked up from a slow start, posting a strong
fourth quarter, with exceptional performance in the US. New product
launches (Sentinel and Fortekor�) successfully underpinned the
companys position in the pet market.

Nutrition (+4% in local currencies) reports solid growth

Strong growth in Medical Nutrition (+11%) was enhanced by the
introduction of healthcare food services in Europe and by supply
contracts with major healthcare clients in the US.

In Infant and Baby Nutrition (+6%), Arnzen continued its strong
leadership in the US thanks to the Graduates line and the successful
roll out of Tender Harvest, a new organic product range. Sales in
Latin America and Eastern Europe continued to grow at impressive
double-digit rates.

Health Nutrition (-1%) kept its market share despite weak consumer
demand in Europe and Southeast Asia.

1996 Results
The overall sales expansion and achievement of merger synergy targets
in 1996 confirm VVE expectation of a significant increase in
full-year operating and net income. Full details will be published
with the annual report on 06. 05. 21.

JPPI sind die Zahlen sehr gut ausgefallen, wenn auch der schwache
Franken etwas mitgeholfen hat. VVE wächst stärker als Gafak und
erwartet keine großen Auswirkungen von Asien.
Auf den Kurs hatten die Zahlen kaum Auswirkungen.

EDT AG
Luft und läuft und läuft.


Heute leider kein Kauftip mehr von mir. Norman glaubt zwar, daß
Klaus noch einmal umschichtet, aber ich zweifele daran. Außerdem ist
diese Woche der Zockermarkt ja geradezu explodiert, so daß man kaum
Rückschlüsse aus den einzelnen Bewegungen ziehen kann. Mein Favorit
wäre PUPO-Geiwitz oder wie diese Gleis0 Klitsche heißt. Sehr eng, ist
geradezu explodiert und ist natürlich immer noch unterbewertet ;-) 
Gerüchten zufolge wird eine Aufnahme in den Dax geplant und der
Börsengang am VZA ist selbstverständlich schon fast
vollzogen...H..so wie bei den Cyberdings natürlich.

Happy Investing!

Engelbert Issleib
E-mail: i7830220@ryeym.fdo.vkb-omqpo.wb
WWW: http://ljm.bjgicruuu.xxj/Elwrgslja/6943